Comparative evaluation of the effect of ibuprofen lysine & gelofen - acetaminophen on postoperative endodontic dental pain with irreversible pulpaitis

开始日期2019-04-21

申办/合作机构

Kermanshah University of Medical Sciences

IRCT20130812014333N131 / Recruiting临床2/3期IIT

comparison of the effect of ibuprofen lysine with gelofen-acetaminophen on postoperative pain of mandibular third molars surgery

开始日期2019-01-10

申办/合作机构

Kermanshah University of Medical Sciences

IRCT2017051934030N1 / CompletedN/AIIT

Comparison between different ibuprophen formulations with two prescription methods on postoperative pain after root canal treatment of teeth with symptomatic irreversible pulpitis; a double blind randomized clinical trial

开始日期2017-09-23

申办/合作机构-

100 项与布洛芬赖氨酸相关的临床结果

登录后查看更多信息

100 项与布洛芬赖氨酸相关的转化医学

登录后查看更多信息

100 项与布洛芬赖氨酸相关的专利（医药）

登录后查看更多信息

项与布洛芬赖氨酸相关的文献（医药）

2024-07-01·European Journal of Clinical Pharmacology

Physicochemical compatibility of caffeine citrate and caffeine base injections with parenteral medications used in neonatal intensive care settings

Article

作者: Batty, Kevin T ; Mukadam, Nabeelah ; Moore, Brioni R ; Petrovski, Michael ; De Silva, D Thisuri N ; Page-Sharp, Madhu ; Strunk, Tobias

AbstractPurposeTo investigate the physicochemical compatibility of caffeine citrate and caffeine base injections with 43 secondary intravenous (IV) drugs used in Neonatal Intensive Care Unit (NICU) settings.MethodsCaffeine citrate (20 mg/mL or 10 mg/mL) or caffeine base injection (10 mg/mL) were mixed in a volume ratio of 1:1 with the secondary drug solution to simulate Y-site co-administration procedures in NICUs. Physical compatibility was evaluated based on visual observation for 2 h, against a black and white background and under polarised light, for changes in colour, precipitation, haze and evolution of gas. Chemical compatibility was determined from caffeine concentration measurements, using a validated high-performance liquid chromatography assay.ResultsSix of the 43 secondary drugs tested (aciclovir, amphotericin (liposomal), furosemide, hydrocortisone, ibuprofen and ibuprofen lysine) were physically incompatible with caffeine citrate undiluted injection (20 mg/mL), at their high-end, clinically relevant concentrations for NICU settings. However, when tested at lower concentrations, hydrocortisone (1 mg/mL) was physicochemically compatible, whereas furosemide (0.2 mg/mL) was physically incompatible with caffeine citrate. The six drugs which showed physical incompatibility with caffeine citrate 20 mg/mL injection were also physically incompatible with caffeine citrate 10 mg/mL solution. All 43 secondary drugs tested were physicochemically compatible with caffeine base injection.ConclusionsMost secondary test drugs, except aciclovir, amphotericin (liposomal), furosemide, hydrocortisone, ibuprofen and ibuprofen lysine, were physicochemically compatible with caffeine citrate injection. Caffeine base injection was physicochemically compatible with all 43 test drugs tested.

2024-05-01·International Journal of Developmental Neuroscience

Early versus late caffeine and/or non‐steroidal anti‐inflammatory drugs (NSAIDS) for prevention of intermittent hypoxia‐induced neuroinflammation in the neonatal rat

Article

作者: Aranda, Jacob V ; Beharry, Kay D ; Cai, Charles L ; Batool, Myra ; Hand, Ivan

AbstractPreterm infants often experience frequent intermittent hypoxia (IH) episodes which are associated with neuroinflammation. We tested the hypotheses that early caffeine and/or non‐steroidal inflammatory drugs (NSAIDs) confer superior therapeutic benefits for protection against IH‐induced neuroinflammation than late treatment. Newborn rats were exposed to IH or hyperoxia (50% O2) from birth (P0) to P14. For early treatment, the pups were administered: 1) daily caffeine (Caff) citrate (Cafcit, 20 mg/kg IP loading on P0, followed by 5 mg/kg from P1‐P14); 2) ketorolac (Keto) topical ocular solution in both eyes from P0 to P14; 3) ibuprofen (Ibu, Neoprofen, 10 mg/kg loading dose on P0 followed by 5 mg/kg/day on P1 and P2); 4) Caff+Keto co‐treatment; 5) Caff+Ibu co‐treatment; or 6) equivalent volume saline (Sal). On P14, animals were placed in room air (RA) with no further treatment until P21. For late treatment, pups were exposed from P0 to P14, then placed in RA during which they received similar treatments from P15‐P21 (Sal, Caff, and/or Keto), or P15‐P17 (Ibu). RA controls were similarly treated. At P21, whole brains were assessed for histopathology, apoptosis, myelination, and biomarkers of inflammation. IH caused significant brain injury and hemorrhage, inflammation, reduced myelination, and apoptosis. Early treatment with Caff alone or in combination with NSAIDs conferred better neuroprotection against IH‐induced damage than late treatment. Early postnatal treatment during a critical time of brain development, may be preferable for the prevention of IH‐induced brain injury in preterm infants.

2023-04-01·Archives of Iranian Medicine

Efficacy of Ibuprofen Lysine on First-Trimester AbortionRelated Pain and Hemorrhage: A Randomized TripleBlinded Clinical Trial

Article

作者: Garrosi, Lida ; Dabiri Oskoei, Atousa ; Amini, Faranak ; Gholami, Hamideh ; Najmi, Zahra ; Tofighi, Shabnam

Background: Some recent trials have reported high efficacy for nonsteroidal anti-inflammatory drugs (NSAIDs) in relieving medical abortion-related pain. The aim of this study was to determine the beneficial effect of oral NSAIDs (ibuprofen lysine) in reduction of pain and hemorrhage in first-trimester medical abortion. Methods: This randomized triple-blinded clinical trial was performed on 98 pregnant women who were candidate for medical abortion within the first-trimester period (gestational age<12 weeks). The participants were randomly assigned to receive ibuprofen lysine (684 mg orally every 4 hours) or placebo. All patients were initially treated with misoprostol (800 µg every 3 hours). Pain intensity and rate of hemorrhage were assessed every hour up to 15 hours after receiving the first dose of misoprostol by visual analogue scaling (VAS) and pictorial blood loss assessment chart (PBAC), respectively. Results: Assessing the mean pain score within 15 hours of receiving misoprostol showed significantly lower pain intensity within the first 10 hours of assessment in the group receiving NSAID in comparison with the control group (P<0.001). The bleeding rate was also significantly lower in the NSAID group at the fifth (P=0.013) and ninth (P=0.040) hour of receiving misoprostol compared to the control group. We found no difference in abortion-related complication rate between the NSAID and placebo groups (8.3% versus 8.0%, P=0.952). Conclusion: The use of NSAIDs (ibuprofen lysine) is a good pharmacological analgesic option for relieving medical abortionrelated pain and hemorrhage.

项与布洛芬赖氨酸相关的新闻（医药）

2022-09-26

·信狐药迅

改良新药依达拉奉舌下片获批上市 | 新获批（9.19-9.25）

每周药品注册受理数据，分门别类呈现，一目了然。新药上市申请药品名称企业名称分类受理号特瑞普利单抗注射液上海君实生物医药科技股份有限公司2.2CXSS21010582.2CXSS2101057依达拉奉舌下片南京百鑫愉医药有限公司2.2CXHS2101030新药临床申请药品名称企业名称分类受理号BT-114143注射液赛诺哈勃药业(成都)有限公司1CXHL2200487EG017片长春金赛药业有限责任公司1CXHL2200493GB5005嵌合抗原受体T细胞注射液上海吉倍生物技术有限公司1CXSL2200313GH55胶囊勤浩医药(苏州)有限公司1CXHL2200499GH55胶囊1CXHL2200500HT-101 注射液苏州星曜坤泽生物制药有限公司1CXHL2200498HTMC0435片上海壹典医药科技开发有限公司1CXHL2200509HTMC0435片1CXHL2200510HTMC0435片1CXHL2200511HTMC0435片1CXHL2200512HTMC0435片1CXHL2200513HTMC0435片1CXHL2200514IBI333信达生物制药(苏州)有限公司1CXSL2200295PM1009注射液普米斯生物技术(珠海)有限公司1CXSL2200312QY201片启元生物(杭州)有限公司1CXHL2200501QY201片1CXHL2200502RBD7022注射液苏州瑞博生物技术股份有限公司1CXHL2200451STI-6129注射液浙江艾森药业有限公司1CXSL2200326XH-5102片上海勋和医药科技有限公司1CXHL22005171CXHL2200518XTN003098深圳众格生物科技有限公司1CXHL22004951CXHL2200496XYP-001健康元药业集团股份有限公司2.2;2.4CXHL2200508靶向GPC3嵌合抗原受体自体T细胞注射液原启生物科技(上海)有限责任公司1CXSL2200304苯乙基异硫氰酸酯液体硬胶囊无锡杰西医药股份有限公司1CXHL22005251CXHL2200526德谷胰岛素注射液通化东宝药业股份有限公司3.3CXSL22003183.3CXSL2200319硫酸阿托品滴眼液艾尔健康眼药(辽宁)有限公司2.4CXHL22004722.4CXHL22004732.4CXHL2200474盐酸杰克替尼片苏州泽璟生物制药股份有限公司1CXHL19004421CXHL1900441盐酸米托蒽醌脂质体注射液石药集团中诺药业(石家庄)有限公司2.4CXHL2200497盐酸纳布啡注射液宜昌人福药业有限责任公司2.4CXHL2200505重组人源化抗TIGIT单克隆抗体注射液乐普生物科技股份有限公司1CXSL2200329注射用BAT8007百奥泰生物制药股份有限公司1CXSL2200330注射用KH617四川弘合生物科技有限公司1CXHL2200491注射用低分子量岩藻糖化糖胺聚糖钠牡丹江友搏药业有限责任公司1CXSL2200305注射用重组替度鲁肽重庆派金生物科技有限公司3.2CXSL2200316仿制药申请药品名称企业名称分类受理号阿卡波糖片贵州天安药业股份有限公司4CYHS2000627阿齐沙坦片兆科药业(广州)有限公司3CYHS2000702奥美沙坦酯氨氯地平片吉林省德商药业股份有限公司3CYHS2101010奥硝唑注射液山东达冠医药科技有限公司3CYHS21012023CYHS2101201康普药业股份有限公司3CYHS21010973CYHS2101096非那雄胺片华润赛科药业有限责任公司4CYHS1900865复方氨基酸注射液(20AA)内蒙古白医制药股份有限公司4CYHS1700480复方聚乙二醇电解质口服液舒泰神(北京)生物制药股份有限公司3CYHS1900137复方聚乙二醇电解质散(儿童型)3CYHS1900125甲苯磺酸艾多沙班片海南先声药业有限公司4CYHS21012334CYHS21012344CYHS2101235来那度胺胶囊石药集团欧意药业有限公司4CYHS2100208赖氨洛芬注射液四川维奥制药有限公司3CYHS2101904利伐沙班片上海普康药业有限公司4CYHS2101091利奈唑胺葡萄糖注射液重庆华邦制药有限公司4CYHS21018064CYHS2101804硫酸特布他林雾化吸入用溶液山东京卫制药有限公司4CYHS2101194氯巴占片宜昌人福药业有限责任公司3CYHS22004353CYHS2200436普瑞巴林缓释片齐鲁制药有限公司3CYHL2200057羟苯磺酸钙胶囊海南林恒制药股份有限公司4CYHS2101050他达拉非片南昌立健药业有限公司4CYHS2100255许昌高新制药有限公司4CYHS2000261碳酸镧咀嚼片南京正大天晴制药有限公司4CYHS2100288碳酸氢钠林格注射液西安万隆制药股份有限公司3CYHS1600153四川美大康佳乐药业有限公司3CYHS1600137吸入用乙酰半胱氨酸溶液江苏吴中医药集团有限公司苏州制药厂4CYHS1900365福安药业集团庆余堂制药有限公司4CYHS1900289江苏康缘药业股份有限公司4CYHS1900069山西优胜美特药业有限公司4CYHS1700604河北仁合益康药业有限公司4CYHS1700541缬沙坦氨氯地平片(Ⅰ)石家庄四药有限公司4CYHS2101486溴莫尼定噻吗洛尔滴眼液江西科伦药业有限公司4CYHS2100055盐酸奥普力农注射液山东海雅医药科技有限公司3CYHS2000939盐酸二甲双胍片盖天力医药控股集团华东药业有限公司4CYHS2100272盐酸鲁拉西酮片丽珠集团丽珠制药厂4CYHS2200572盐酸帕罗西汀肠溶缓释片北京福元医药股份有限公司4CYHS21012084CYHS2101207盐酸替罗非班氯化钠注射液湖南科伦制药有限公司3CYHS21001503CYHS2100151盐酸托莫西汀口服溶液山东达因海洋生物制药股份有限公司4CYHS2100013盐酸溴己新颗粒江西亿友药业有限公司3CYHS2100274依达拉奉注射液哈尔滨三联药业股份有限公司3CYHS2000592注射用阿扎胞苷健进制药有限公司4CYHS2000897注射用艾司奥美拉唑钠杭州澳亚生物技术有限公司4CYHS2000871注射用奥美拉唑钠(静脉滴注)山东丹红制药有限公司4CYHS2100240注射用达托霉素齐鲁制药(海南)有限公司4CYHS2100034注射用米卡芬净钠扬子江药业集团有限公司4CYHS1900872注射用头孢曲松钠/氯化钠注射液湖南科伦制药有限公司3CYHS1700125左氧氟沙星片石家庄格瑞药业有限公司4CYHS20009404CYHS2000938唑来膦酸注射液石药集团欧意药业有限公司6CYHS1401431进口申请药品名称企业名称分类受理号BLU-945胶囊再鼎医药(上海)有限公司1JXHL2200176BLU-945胶囊1JXHL2200177Difamilast软膏大冢制药研发(北京)有限公司5.1JXHL2200163Difamilast软膏5.1JXHL2200164Difamilast软膏5.1JXHL2200165MK-4280A注射液默沙东研发(中国)有限公司1JXSL2200126MK-4830注射液1JXSL2200109RO6868847薄膜包衣片罗氏(中国)投资有限公司1JXHL2200173RO6868847薄膜包衣片1JXHL2200174RO70828591JXSL2200124Talquetamab注射液强生(中国)投资有限公司1JXSL22001211JXSL2200122Xevinapant口服溶液默克雪兰诺(北京)医药研发有限公司1JXHL2200180奥拉帕利片阿斯利康投资(中国)有限公司5.1JXHS21011045.1JXHS2101103枸橼酸西地那非口溶膜晖致医药有限公司5.1JXHL2200175帕博利珠单抗注射液默沙东研发(中国)有限公司2.2JXSL2200110萨特利珠单抗注射液罗氏(中国)投资有限公司2.2JXSL22001122.2JXSL2200113溴吡斯的明缓释片北京罕友医药科技有限公司5.2JYHL2200001左乙拉西坦片阿乐滨度(上海)贸易有限公司5.2JXHS18000055.2JXHS18000075.2JXHS1800006中药相关申请无。注：灰色字体部分结论为不批准；不包含原料药、医用氧、注射用水、氯化钠或葡萄糖注射液等申请，不包含再注册、一次性进口、技术转移、复审申请。

抗体

2022-09-20

·药讯社

快讯！NMPA：4个上市申请未通过，含化药3、4类等！3品规过评失败（含2家阿司匹林肠溶片）！

前言：今日（9月20日），NMPA发布的药品通知件待领取信息（13个）：4个上市申请和9个补充申请（含3个一致性评价）在列。出现在通知件内，意味着被毙（不予批准）或者主动撤回！小编暂未知上述品规的具体情况，不过值得关注的是多数申请人为知名企业。（1）4个上市申请：1个原化药6类（唑来膦酸注射液）、1个化药3类（赖氨洛芬注射液）、2个化药4类（注射用阿扎胞苷、盐酸鲁拉西酮片）。（2）2家药企（桂林南药股份有限公司、乐普恒久远药业有限公司）的阿司匹林肠溶片过评失败。截至目前，国内仅有辰欣药业股份有限公司的阿司匹林肠溶片过评成功（2021年8月12日）。

100 项与布洛芬赖氨酸相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D06606	布洛芬赖氨酸	M02AA13 R02AX02 M01AE01 G02CC01 C01EB16	DBSALT001397

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
动脉导管未闭	美国	Recordati Rare Diseases, Inc.	2006-04-13
头痛	英国	Reckitt Benckiser Healthcare (UK) Ltd.	2006-01-17
偏头痛	英国	Reckitt Benckiser Healthcare (UK) Ltd.	2006-01-17

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
痛经	临床1期	-	Merck Sharp & Dohme Corp.	2016-02-11
动脉导管未闭	药物发现	-	Farmacon	2002-12-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02452450 (Pubmed \| Curr Med Res Opin)	临床1期	-	32	Ibuprofen lysine	鏇選艱襯艱願襯襯鬱鹹(膚襯積鏇蓋遞積膚鹽糧) = 鹽顧遞願築艱窪鑰鑰構觸積願顧壓蓋網鹽製壓 (選築廠觸製窪窪夢鬱衊 )	-	2018-08-01
				Ibuprofen liquid capsule	鏇選艱襯艱願襯襯鬱鹹(膚襯積鏇蓋遞積膚鹽糧) = 遞鏇糧積餘齋齋遞觸範觸積願顧壓蓋網鹽製壓 (選築廠觸製窪窪夢鬱衊 )